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Abstract This article describes a rapid LC–MS/MS target
screening method based on an automated extraction of 5 lL
dried blood spots (DBS), two 5 min chromatographic runs
on orthogonal phase columns (RP and Hilic) and a data
dependent acquisition (DDA) of product ions spectra for the
reliable identification of the detected compounds. The
extraction step was performed in 2 min by using the LC
autosampler itself in 96-well plates. This procedure
was evaluated using 22 model compounds frequently
encountered in forensic investigations, i.e., cocaine, benzo-
diazepines, amphetamines, opioids, antidepressants and
antipsychotics. These investigations showed that even if the
extraction step was reduced to a minimum, the extraction
recoveries were satisfactory (median value of 40 %) and
allowed for the detection of the model compounds in their
therapeutic ranges, with the exception of morphine. More-
over, the use of two different chromatographic columns
broadened the number of screening targets to those that
behaved poorly under RP conditions, such as amphetamines
or glucuronides, while keeping chromatographic gradients
very short. This procedure was applied to 34 authentic post-
mortem cases. It allowed the detection of 89 % of the
compounds that were quantified in the routine proce-
dures and the formal identification of 77 % of the com-
pounds using their product ions spectra. These results were
considered more than satisfactory compared to routine
screening alone (GC–MS and LC-DAD, 55 % compound
identification). The method described in this article is
therefore a powerful approach for a fast, reliable and effi-
cient target screening of drugs in forensic and clinical
investigations.
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Introduction
Drug screening is an important issue in clinical and
forensic toxicology that provides essential information for
both making a diagnosis and confirmatory quantitative
analysis. A screening procedure should ideally enable the
detection and identification of any substance of toxico-
logical interest in biological fluids. As the detection capa-
bility strongly depends on the matrix, sample preparation
and analysis technique, toxicological screening generally
consists of a combination of complementary analytical
procedures, primarily immunoassays, chromatography and
mass spectrometry. This combination gives a precise
overview of the substances that were taken [1]. This
approach is usually called systematic toxicological analysis
(STA). Urine, blood, oral fluid and hair are the most
common matrices for forensic STA procedures, each of
which providing a different consumption time window [2].
Blood samples (i.e., whole blood, plasma and serum)
have a particular value for forensic investigation, as they
give information on the acute state of the patient [2, 3].
However, collecting blood from a living patient is much
more invasive than urine and requires medical supervision
and particular logistics [4]. Furthermore, in post-mortem
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investigations, volumes of blood may be too scarce to
perform any analysis [5].
The use of dried blood spots (DBS) can help because
they represent a fast, simple and economical way to collect
blood material [6]. A small amount of blood (typically
5–25 lL), obtained from post-mortem cases or directly
after a finger prick on living patients, is spotted onto a
cellulose card. Shipment and storage can then be performed
without dry ice or refrigeration because most of the ana-
lytes are stable at ambient temperature, greatly facilitating
handling in this sampling format [7].
Traditionally used for neonatal screening of metabolic
disorders, the DBS approach has been extended to different
biomedical applications, including therapeutic drug moni-
toring, clinical and preclinical trials, epidemiological
studies and disease surveillance [7]. Although some liter-
ature has assessed the potential of DBS for drug screening,
especially in doping analysis [8], this alternative sampling
method has not yet been implemented for forensic
applications.
Gas chromatography coupled to mass spectrometry
(GC–MS) is still considered the gold standard for STA [9],
but liquid chromatography coupled to mass spectrometry
(LC–MS) is now well established as a powerful alternative
for screening blood [3, 10]. The latter method increases the
screening capabilities for polar and non-volatile com-
pounds and simplifies sample preparation. Reversed Phase
(RP) LC is generally used in screening procedures, as it
enables the separation of a wide variety of analytes.
Methods have been published to enhance the separation
capabilities of LC systems using an orthogonal phases
column-switching set-up [11, 12]. Though this approach
has high potential, its implementation is relatively com-
plex, which has limited its use in toxicological laboratories.
The coupling of RP HPLC to single MS has been
described [13, 14], but tandem MS could greatly improve
the selectivity of these screening methods [15, 16]. In this
configuration, identification of unknown compounds is
generally based on product ion spectra acquired on low-
resolution mass spectrometers, such as tridimensional ion
trap (3D IT) or linear ion trap (LIT) instruments. These
instruments feature a fast scanning speed in full scan mode
and allow MSn experiments, which greatly improve the
identification capabilities. Using this type of setup, proce-
dures have been published that allow the general unknown
screening of drugs [16–18]. Effective multi-target screen-
ing applications have also been published [19–21], signif-
icantly increasing selectivity and sensitivity due to the
concomitant use of multiple reactions monitoring (MRM)
acquisition with product ion scans. For this, hybrid systems
(QqQLIT) coupling the advantages of a triple quadrupole
platform (QqQ) with a LIT are employed in data-dependent
acquisition (DDA) mode [22].
Sample preparation is a crucial step in screening pro-
cedures. Indeed, it is essential to remove matrix compo-
nents that could impair the detection and identification
performance without eliminating the compounds of inter-
est. Off-line procedures are typically used for this purpose,
including liquid–liquid extraction (LLE) and solid phase
extraction (SPE) [3]. Although these procedures are well
described, they are tedious and time consuming, which
hinder rapid drug screening. Thus, alternatives have been
proposed to improve analytical throughput, such as on-line
SPE, turbulent flow chromatography (TFC) [23] and dilute-
and-shoot approaches [24].
Sample preparation should ideally be rapid, simple, on-
line and automated. Recently, our group showed that,
besides its well-described benefits from the medical and
logistical points of view [25], dried blood spot (DBS)
sampling allows for greatly simplifying the extraction
procedure without sacrificing excellent analytical perfor-
mance [26]. The purpose of this work was to propose an
automated on-line DBS extraction procedure prior to rapid
LC–MS/MS target screening of drugs as a complementary
tool for STA. DBS of 5 lL were considered in this work, as
this is the laboratory standard format for quantitative
analysis. The benefits gained through the use of two col-
umns with orthogonal phases were also investigated.
Materials and Methods
Chemicals and Samples
All reference compounds and deuterated analogs were pur-
chased at 1,000 lg/mL or 100 lg/mL in methanol (MeOH)
or other suitable solvent from Cerilliant (Round Rock, USA)
or Lipomed (Arlesheim, Switzerland). Working standard
mixtures were prepared by diluting these stock solutions in
MeOH to obtain the concentration of interest. A solution of
trimipramine-d3, used as a chromatographic standard (CS),
was prepared separately at 10 ng/mL in MeOH. This solu-
tion was used as the extractive solvent. After use, stock and
working solutions were stored at -20 C.
Both acetonitrile (ACN) and MeOH were of high-perfor-
mance chromatographic grade from Merck (Darmstadt,
Germany). The 200 mM formate buffer (FB) was prepared
from ammonium formate (Fluka). A pH of 3.2 was obtained
by adjusting with 1 % aqueous hydrochloric acid (Merck).
All human blood, including blank blood, was supplied by the
University Center of Legal Medicine (Geneva, Switzerland).
Preparation of Spiked Blood
Fresh blank whole blood was spiked to the concentrations of
interest for 22 model compounds (i.e., cocaine, cocaethylene,
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benzoylecgonine, ecgonine methylester (EME), amphetamine,
3,4-methylenedioxy-N-methylamphetamine (MDMA), meth-
amphetamine, morphine, morphine-3-glucuronide (morphine-
glu), 6-monoacetylmorphine (6-MAM), codeine, methadone,
diazepam, 7-aminoclonazepam, midazolam, a-hydroxymi-
dazolam (OH-midazolam), zolpidem, amitriptyline, citalo-
pram, trimipramine, clozapine and haloperidol) by adding a
suitable volume of the corresponding stock solution to a
plastic microtube. The solvent was then evaporated to dryness
under a gentle stream of nitrogen, and blood was added to the
residue. The spiked blood was then vortexed to ensure the
dissolution of the analytes. The DBS obtained from spiked
blood were designated as spiked DBS in this work.
Sample Pre-Treatment
5 lL of real or spiked whole blood was spotted on a filter
paper card protein saver 903 from Whatman (Dassel,
Germany) using a volumetric micropipette (Eppendorf,
Hamburg, Germany). The blood spots were allowed to dry
at room temperature for 1 h and then packed in a sealable
plastic bag containing desiccant until analysis. These
samples were stored in the dark at ambient temperature.
Discs 6 mm in diameter that covered the entire DBS
were punched out and directly introduced into a 96-well
plate. Extraction was performed by the LC autosampler
itself as follows. First, 100 lL of MeOH containing the CS
was introduced into the desired well by the autosampler
syringe. Mixing was produced by dispensing 100 lL of air
three times in the extraction well through the syringe, and
then by aspirating and dispensing 50 lL of the well con-
tents twice. This operation lasted 2 min. After rinsing the
syringe internally and externally with ACN, 5 lL of the
extract was injected into the chromatographic system.
Dual LC
The DBS analysis was performed using a LC–MS/MS
system consisting of a 5500 QTrap (QqQLIT) mass
spectrometer equipped with a TurboIon SprayTM interface
(AB Sciex, Concord, Canada) and an Ultimate 3000 RS
pump (Dionex, Sunnyvale, CA, USA) as the LC system.
Data were acquired and processed using Analyst software
(version 1.5.2; AB Sciex, Toronto, Canada).
Two columns were set up in parallel (Fig. 1) to achieve
chromatographic separation: a 50 mm 9 2.1 mm i.d.,
2.6 lm Kinetex RP C18 column and a 50 mm 9 2.1 mm
i.d., 2.6 lm Kinetex Hilic column (Phenomenex, Torrance,
USA). For the RP column, the mobile phase (MP) con-
sisted of a mixture of H2O and ACN set at a flow rate of
0.6 mL/min, while a mixture of H2O, ACN and FB at a
flow rate of 0.7 mL/min was used for the Hilic column.
The chromatographic run was divided into two phases,
corresponding to the subsequent injections of the same
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Fig. 1 HPLC setup featuring the two columns used in parallel. Pump 1 was linked to the RP column and pump 2 to the Hilic column. In RP
mode, valves were in positions 1–2 and 1–2, and they were switched to positions 1–10 and 1–6 in Hilic mode
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sample on the RP (RP mode) and Hilic (Hilic mode) col-
umns. Gradients applied on the two columns during both
phases are described in Fig. 2. In RP mode, ACN/H2O was
set to 2/98 v/v for 0.1 min on the RP column and then
brought to 90/10 over 1.9 min. These proportions were
maintained for 2 min, and the column was then flushed
with 100 % ACN. Meanwhile, the Hilic column was flu-
shed with ACN/H2O/FB (50/48/2, v/v/v) for 1 min, and
then equilibrated to the initial conditions of the Hilic mode.
In the Hilic mode, ACN/H2O/FB was set to 97/1/2 for
0.5 min on the Hilic column and then brought to 60/38/2 in
2.5 min. These proportions were maintained for 1 min, and
then the column was flushed with 50/48/2. Meanwhile, the
RP column was flushed with 100 % ACN for 1 min and
then equilibrated to the RP mode initial conditions.
The TurboIon Spray interface was operated in the
positive ionization mode. Nitrogen was used as the curtain
and nebulizer gas, and the source parameters were set to a
temperature of 650 C, a capillary voltage of 5,000 V, an
entrance potential of 10 V, a collision cell exit potential of
10 V, a curtain gas pressure of 20 psi, a nebulizer gas
(GS1) pressure of 30 psi, and an auxiliary gas (GS2)
pressure of 40 psi.
A data dependent acquisition (DDA) was defined to
acquire the MS data as follows: selected reaction moni-
toring (SRM) transitions based on collision-induced dis-
sociation (CID) occurring in the collision cell (quadrupole
2) were acquired. Then, 191 and 181 SRM transitions for
the RP and the Hilic mode, respectively, were gathered
from the method applied in our laboratory and from the
iMethodTM Forensic LC/MS/MS Spectral Library (version
2.0) supplied by AB Sciex. If the signal for one of the
transitions reached a defined threshold (5,000 and 15,000
cps for the RP and the Hilic mode, respectively), an
enhanced product ion (EPI) spectrum was acquired with
collision energies of 40, 60 and 80 eV. To avoid missing
co-eluted compounds, ions for which a mass spectrum was
acquired were excluded 5 s after one occurrence.
Detection and Identification
A compound detection was accepted if a peak with a signal-
to-noise (S/N) ratio greater than three was observable in the
corresponding SRM transition at the correct retention time.
When an EPI spectrum was acquired for the detected com-
pound, SmileMS (version 1.1; GeneBio, Geneva, Switzer-
land) was used to identify the compound present in the
sample by comparing the acquired spectrum with a spectral
database. The database used in this study was created by
merging the iMethodTM Forensic LC/MS/MS Spectral
Library (version 2.0) and spectra acquired on our instrument.
The minimum match factor for identification was set to 50.
Evaluation of the Method
The process efficiency was evaluated using the approach of
Matuszewski et al. [27], with adaptations for the sample
preparation. Three parameters were measured in triplicate for
the 22 selected model compounds: the extraction recoveries
were calculated by comparing the absolute analyte peak area
of spiked DBS (100 ng/mL) to those obtained from the
corresponding methanolic solution (5 ng/mL) introduced in
wells containing blank DBS. Filter paper and the matrix
effects were estimated by comparing the absolute analyte
peak area of methanolic solutions introduced in wells con-
taining blank filter paper disks and blank DBS, respectively,
to those obtained from the corresponding methanolic solu-
tion. Finally, the overall analyte recoveries were measured by
comparing the absolute analyte peak area of spiked DBS to
those obtained from the corresponding methanolic solution.
The limits of detection (LOD) were evaluated by
injecting extracts of spiked DBS with concentrations of 1,
5, 10, 50, and 100 ng/mL of each analyte. LOD was
defined as the lowest concentration giving a peak, with a
signal-to-noise ratio greater than 3. The limits of identifi-
cation (LOI) correspond to the lowest concentrations from
which SmileMS was able to identify the compound.
Fig. 2 Gradients used on the
two columns. Continuous and
dashed lines represent the
gradients applied on the RP and
Hilic columns, respectively
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The described screening approach was then evaluated by
quality control for benzodiazepines (Benzodiazepines plus
100 whole blood toxicology control) and pain management
drugs (PM 100 (WB) whole blood toxicology control) from
UTAK Laboratories (Valencia, USA), opioids substitution
drugs (Medidrug OSD 1/12-B VB) and drugs of abuse
(Medidrug DOA-I VB low) from MEDICHEM Diag-
nostica (Steinenbronn, Germany), and 34 authentic post-
mortem samples received in our laboratories. The results
obtained by LC–MS/MS were compared to those obtained
during routine STA (i.e., GC–MS and LC-DAD) screening
on whole blood (1 mL), as well as GC–MS(/MS) and
LC–MS/MS quantitative analysis. Twenty different blank
blood samples were also injected to evaluate the selectivity
of the method, and carry-over was controlled by injecting
blank MeOH after each sample injection.
Results and Discussion
Sample Preparation
In addition to its already well-known advantage of sample
collection, DBS has also been described as a very
promising technique to simplify sample preparation prior
to analysis. Indeed, a simple soak of 5 lL DBS in methanol
proved to be sufficient to quantitatively and cleanly extract
a class of drugs and quantify them within their therapeutic
range [26]. This approach is all the more interesting for
screening applications because methanol is a good solvent
for a wide range of compounds, which makes this proce-
dure theoretically compatible with many drug classes.
Extraction investigations showed that the automated
procedure yielded extraction recoveries from 10 to 100 %,
with a median extraction recovery of 40 % (Table 1). This
recovery was considered satisfactory regarding the fact that
the extraction procedure was reduced to a minimum. No
direct correlation between the extraction recovery and the
hydrophilicity (expressed as log P) of the selected
compounds could be observed, which indicated that this
approach might be suitable for compounds with very dif-
ferent physico-chemical properties. For the compounds that
were detectable in both chromatographic runs, the extrac-
tion recovery was noticed to be higher for the second
injection. As already described [26], the extraction was
not complete after 2 min, suggesting that the extrac-
tion performance could be improved with an increased
Table 1 Matrix effects, extraction recoveries and overall process efficiencies for 22 model compounds, as estimated for the two chromato-
graphic runs
Compound log P Matrix effect Extraction recoveries
(RP/Hilic) (%)
Overall process efficiency
(RP/Hilic) (%)
Paper (RP/Hilic)
(%)
Blood (RP/Hilic)
(%)
Overall (RP/Hilic)
(%)
Cocaine 3.08 114/106 93/57 107/60 49/60 52/36
Cocaethylene 2.79 110/98 89/62 98/61 47/58 46/35
Benzoylecgonine 2.26 88/89 133/85 118/75 34/10 40/8
EME 0.13 –/73 –/21 –/15 –/77 –/12
Amphetamine 1.81 –/98 –/53 –/52 –/63 –/33
MDMA 2.05 –/96 –/30 –/28 –/74 –/21
Methamphetamine 2.20 –/10 –/22 –/22 –/105 –/23
Morphine 0.87 114/– 64/– 73/– 20/– 15/–
6-MAM 1.20 –/113 –/103 –/117 –/38 –/45
Morphine-Glu -1.56 –/70 –/115 –/80 –/17 –/14
Codeine 1.20 –/125 –/25 –/31 –/40 –/12
Methadone 3.93 107/99 93/92 100/91 36/56 35/51
Diazepam 2.80 110/– 83/– 91/– 42/– 39/–
7-Aminoclonazepam 1.29 87/– 121/– 105/– 25/– 26/–
Midazolam 3.80 99/– 97/– 96/– 48/– 46/–
Hydroxymidazolam 2.50 99/– 106/– 105/– 40/– 42/–
Zolpidem 4.41 94/– 95/– 89/– 35/– 31/–
Amitriptyline 3.48 96/– 95/– 91/– 32/– 29/–
Citalopram 4.71 93/– 98/– 91/– 42/– 39/–
Trimipramine 3.94 96/101 96/83 93/84 32/44 30/37
Clozapine 3.76 103/– 88/– 90/– 29/– 27/–
Haloperidol 0.87 83/– 107/– 89/– 33/– 29/–
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extraction period. This was found to be unnecessary for this
application.
Matrix effect was also evaluated, taking into account the
effect of the filter paper and the blood (Table 1). No or
minor effects were found when only clean filter paper was
introduced into the methanolic solution of the selected
model compounds, suggesting that no particular trapping
effect or release of interfering compounds from the paper
occurred during the extraction procedure. The presence of
blank matrix revealed that interfering compounds extracted
from blood impaired the detection of the compounds of
interest. However, this effect was noticeable only when
injecting on the Hilic column, which retained molecules
with polar moieties. Consequently, a purification step as
well as a more specific chromatographic gradient would
have been necessary to eliminate phospholipids and other
amphiphiles or polar interferences if a quantitative appli-
cation was desired. For qualitative purposes, these matrix
effects were found to be acceptable, as long as they did not
dramatically impair the sensitivity.
The injection of blank methanol after the analysis of
authentic samples showed no carry-over. This was also
observable in MeOH injected after samples containing
high concentrations of methadone (710 ng/mL), sertraline
(1,600 ng/mL) and maprotiline (6,900 ng/mL), which pre-
sented no remaining peaks in the corresponding transitions.
This proved that the rinsing of the syringe after the extrac-
tion step and the flushing of the columns after the chro-
matographic runs were satisfactory. Carry-over was low also
because the extract was not pre-concentrated during the
extraction procedure, which avoided injecting very high
concentrations of drugs into the analytical system.
Dual LC
The major difficulty when developing a screening proce-
dure is to cover the wide range of compounds that may be
encountered in toxicological investigations as completely
as possible. Due to the variety of drug structures and
chemical properties, the emergence of a one-shot universal
screening procedure is elusive. Column switching setups
with orthogonal phases were proposed to expand the
number of drugs amenable to separation, but these systems
required long and complex chromatographic runs to enable
satisfactory resolution.
The strategy that we have adopted in our laboratory was
to reduce the analytical runs to increase throughput. We
chose to set up two chromatographic columns with orthog-
onal phases in parallel (Fig. 1) to broaden the analytical
capabilities of our system while keeping the chromato-
graphic gradients very short and generic. Moreover, making
two injections reduced the post-analysis time, as recondi-
tioning of one column could be conducted while a separation
was running on the other (Fig. 2). This approach is partic-
ularly interesting for screening both nonpolar compounds,
such as benzodiazepines, and polar compounds, such as
amphetamines, which do not respond well to RP conditions,
or metabolites, such as glucuronides. This system was found
to be stable, as standard deviations of 0.31 and 0.51 % over
52 injections were measured on the RP and Hilic columns,
respectively, for CS retention time.
Table 2 shows that most of the compounds present in
different commercial controls covering frequently encoun-
tered drug families were detectable in the RP run under the
described chromatographic conditions, provided the SRM
transition was in the method. In this way, 67 % of the
compounds were visible in the first run. On the second run,
only 28 % of the compounds were detected. This discrep-
ancy was due to the bad chromatographic behavior of the
very nonpolar benzodiazepines on this phase. Nevertheless,
amphetamines were detectable only on the Hilic column.
Therefore, the use of two columns with orthogonal
phases allowed for detection of 80 % of the drugs present
in the controls for which a SRM transition was known.
However, the method did not allow the detection of can-
nabinoids, mainly due to their very low concentrations in
the controls and bad responses to the MS conditions.
Detection and Identification
The use of DBS is limited by the sensitivity of the
instrument. The volume of the DBS sample is very low,
and the analytes cannot be pre-concentrated during the
sample preparation step described in this work. MS/MS is
then mandatory to lower the detection limits, as it enables a
drastic reduction in the noise. However, even if tandem
mass spectrometry is a very selective technique, a single
SRM transition is not sufficient to formally identify the
detected compounds. This is particularly true for multi-
analyte procedures in complex matrices, for which cross-
detections and interferences cannot be exhaustively inves-
tigated. Moreover, methods with several SRM transitions
for each compound become more difficult to manage as the
number of targets increases. To bypass this problem, a
DDA program was implemented that allowed combining
the very high sensitivity of SRM transitions with the good
specificity of EPI spectra.
Table 3 indicates the LOD and LOI for the 22 model
compounds. These two values may differ because LOD is
based on the signal-to-noise ratio, whereas the LOI is based
on the peak intensity. The LOI is then directly linked to the
threshold set in the DDA program to acquire the EPI
spectra, and may be lowered if required. In the conditions
that were used for this work, LOD and LOI were found to
be satisfactory in comparison with the therapeutic ranges
found in the literature [28] or the positivity thresholds
1286 F. Versace et al.
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Table 2 Detection and identification of substances present in four commercial quality controls
Compound Concentrations (ng/mL) Retention time (min, RP/Hilic) Identification
UTAK Benzodiazepines plus 100 whole blood toxicology control
Alprazolam 100 2.60/– 4
Hydroxyalprazolam 100 2.54/– 9
Bromazepam 100 – 9
Chlordiazepoxyde 100 2.68/– 9
Clobazam 100 2.74/– 9
Clonazepam 100 2.64/– 4
7-Aminoclonazepam 100 2.30/– 4
Diazepam 100 2.87/– 4
Nordiazepam 100 2.71/– 9
Estazolam 100 Transition missing 9
Flunitrazepam 100 2.71/– 4
7-Aminoflunitrazepam 100 2.38/– 9
Flurazepam 100 2.88/– 4
2-Hydroxyethylflurazepam 100 Transition missing 9
Lorazepam 100 2.60/– 9
Lormetazepam 100 2.74/– 4
Midazolam 100 2.81/– 4
Hydroxymidazolam 100 2.63/– 4
Nitrazepam 100 2.60/– 9
7-Aminonitrazepam 100 2.27/– 9
Oxazepam 100 2.57/– 4
Prazepam 100 3.11/– 4
Temazepam 100 2.69/– 4
Triazolam 100 2.62/– 9
Hydroxytriazolam 100 Transition missing
Zolpidem 100 2.65/– 4
Medidrug DOA-I VB low
Amphetamine 11 –/3.41 4
MDA 15 –/2.85 9
MDE 16 –/2.80 4
MDMA 16 –/2.89 4
Methamphetamine 16 –/2.89 9
MBDB 21 Transition missing
Cocaine 10 2.68/2.93 4
Benzoylecgonine 16 2.10/– 4
Egonine methyl ester 16 –/3.26 4
Morphine 11 – 9
Codeine 22 – 9
Dihydrocodeine 21 – 9
THC 1 – 9
11-OH-THC 2 – 9
THC-COOH 10 – 9
Cocaethylene 15 2.82/2.90 4
Medidrug OSD 1/12-B VB
Buprenorphine 5 – 9
Norbuprenorphine 8 – 9
Methadone 100 3.20/2.72 4
EDDP 30 3.13/2.75 4
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defined by the Swiss authorities [29], except for morphine.
This compound was difficult to detect due to its incomplete
extraction, the presence of matrix effect in the Hilic mode
and its poor chromatographic performance in the RP phase.
This approach is limited by the number of available SRM
transitions but enables the detection of most compounds of
toxicological interest. Another limitation is that the cycle
time of DDA is relatively long (1.3702 and 1.3101 s for the
RP and Hilic runs, respectively) in comparison with the peak
widths (3 to 20 s, depending on the compound). This means
that the system is not able to acquire a mass spectrum if the
peak is not at least three times as large as the cycle time,
which corresponds to two acquisition points, and cannot
acquire a mass spectrum for coeluted compounds if the peak
widths are not sufficient. This is the reason why not all the
benzodiazepines in Table 2 could be identified by Smile MS
even when a SRM signal was perfectly defined. However,
the concomitant presence of 25 benzodiazepines in one real
case sample is not likely to happen. More generally, the
decision to exclude identified compounds in the DDA pro-
gram can be made by a toxicologist to focus on compounds
for which no EPI spectrum can be acquired. This strategy is
all the more reasonable because the entire screening proce-
dure lasts only 12 min.
Application to Authentic Samples
To evaluate the method, 20 different blank blood samples
and 33 authentic post-mortem cases were analyzed using
Table 3 Limits of detection (LOD) and identification (LOI)
estimated for 22 model compounds
Compound LOD
(ng/mL)
LOI
(ng/mL)
Therapeutic
range–legal
threshold
(ng/mL)
Cocaine \1 1 15
Cocaethylene \1 1 –
Benzoylecgonine 1 5 –
EME 10 10 –
Amphetamine 1 10 15
MDMA 1 10 15
Methamphetamine 10 50 15
Morphine 100 [100 15 (free form)
6-MAM 5 50 –
Morphine-Glu 10 50 –
Codeine 50 100 30–250
Methadone \1 1 100–500
Diazepam 50 50 200–2,000
7-Aminoclonazepam 100 100 –
Midazolam \1 5 40–100
Hydroxymidazolam 5 5 –
Zolpidem \1 1 80–150
Amitriptyline \1 5 50–300
Citalopram \1 5 10–200
Trimipramine \1 1 10–250
Clozapine \1 5 300–600
Haloperidol \1 1 5–20
Table 2 continued
Compound Concentrations (ng/mL) Retention time (min, RP/Hilic) Identification
UTAK PM 100 (WB) whole blood toxicology control
Buprenorphine 10 – 9
Norbuprenorphine 10 – 9
Codeine 100 2.10/– 4
Fentanyl 10 2.88/2.76 4
Norfentanyl 10 Transition missing
Hydrocodone 100 2.31/– 4
Hydromorphone 100 1.96/– 4
Meperidine 100 3.20/2.73 4
Methadone 100 3.14/2.76 4
EDDP 100 3.14/2.76 4
Morphine 100 1.95/– 9
Oxycodone 100 2.46/– 4
Oxymorphone 100 – 9
Tapentadol 100 Transition missing
Tramadol 100 2.53/2.82 4
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the method described in this work. No false positive match
was observed in the 20 blank samples, indicating good
selectivity of the screening method. The results from
screening authentic post-mortem samples are presented in
Table 4. To simplify the results table, the detection of
metabolites is mentioned only if the parent drug was not
detected. Moreover, substances of lower toxicological
interest, such as caffeine or nicotine, are not mentioned.
This study showed that the DBS-LC–MS/MS target
screening approach provided very satisfactory results
compared to routine screening procedures, even if the
sample volume was reduced from 1,000 to 5 lL. Specifi-
cally, routine screening enabled the detection of 55 % of
the drugs that were finally quantified, whereas the pre-
sented method allowed identification of 77 % of them. This
number was elevated to 89 %, if we also considered the
SRM detections that did not trigger the EPI acquisition.
Some compounds could not be detected due to missing
SRM transitions (diltiazem and duloxetine), which illus-
trated the limits of the target screening approach. Some
compounds were also not compatible with the analytical
approach presented in this work (valproic acid and phe-
nobarbital). Morphine and codeine were frequently missed,
and cannabinoids could not be detected in any sample, as
also observed for routine methods.
Conclusion
A rapid target screening procedure for forensic and clinical
applications was proposed in this report. The use of DBS
sampling allowed for the development of a very fast and
simple sample preparation method that maintained good
qualitative analysis performance. This step was easily
automated without a dedicated instrument, which makes
this approach easily implementable in any toxicological
laboratory. The chromatographic setup presented in this
article enabled increased separation capability while
maintaining very short gradients and good chromato-
graphic stability. Finally, very good detection and identi-
fication were observed due to the combination of the
sensitivity of the SRM transitions and the very high spec-
ificity of the EPI spectra. This procedure proved to be a
very powerful tool for forensic and clinical STA.
This method did show some limitations, particularly for
morphine and cannabinoids, which were difficult to detect.
Moreover, some compounds were not detected, as their
SRM transitions were not known. This latter aspect was
inherent to the target screening approach. Finally, the
coupling of the sample preparation and dual LC separation
methods to a more general detection and identification
procedure, including high resolution MS, is perfectly
feasible.T
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